NYSE · ELAN

Elanco Animal Health Incorporated

$25.41 +$0.50 (+2.01%) 1D After hours
Session Pulse After hours 3 mentions today 3 SEC filings since Tue close 4 4 4 its sector ranked 5/11 this week Full pulse →

Key Metrics

$12.44B
Market cap
P/E · TTM
$4.89B
Revenue · TTM
−$242.00M
Net income
EPS · TTM $-0.48
Dividend yield
Free cash flow $315.00M
Beta · 1Y 1.48
EBITDA · TTM $494.00M
Gross margin 55.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 28
    3 insider transaction filings hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4 × 3, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 19
    From its Feb 25 high, the share price fell 26%.

    Peak close $26.84 on Feb 25; trough close $19.80 on May 19. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -26%
  • May 7
    The stock moved -8.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7
  • May 6
    The stock moved +13.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$12.44B
Enterprise value$15.82B
Shares outstanding499.4M
52-wk range$13.39 – $27.72
Avg volume · 20D5.3M
Net cash −$3.38B
Book value / share$13.02
IndustryPharmaceutical Preparations
ExchangeNYSE
About Elanco Animal Health Incorporated
IPO dateSep 20, 2018
Employees9900

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.54
P/FCF39.50
EV/EBITDA32.03
EV/Sales3.23
Graham №

Profitability

Gross 55.1%
Operating -4.0%
Net -4.9%
FCF 6.4%
ROE / ROIC -3.8% · -2.4%

Financial Health

Current ratio2.16
Quick ratio1.12
Debt / equity0.59
Debt / EBITDA 7.71
Net cash −$3.38B
Working capital$1.92B

Cash Flow · TTM

Operating CF $577.00M
Capex −$262.00M
Free cash flow $315.00M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

1.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings